Health Care Technology
Company Overview of Molecular Health AG
Molecular Health AG, a clinico-molecular informatics company, develops precision medicine by translating patient-specific molecular and genomic data, clinical history, and published scientific and medical evidence into drug choices for patients. The company offers clinico-molecular informatics solutions ranging from a drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support system that transforms genome sequences into evidence-based treatment strategies for cancer patients. Its solutions analyze and synthesize extensive bodies of molecular, biomedical, and clinical evidence; map results to a patient’s clinico-molecular sta...
Founded in 2004
Key Executives for Molecular Health AG
Senior Vice President of Finance
Chief Operating Officer and Executive Vice President
Compensation as of Fiscal Year 2014.
Molecular Health AG Key Developments
MolecularHealth Provides Unprecedented Reimbursement Support with RxAssistance
Aug 21 14
MolecularHealth announced an important new component of its TreatmentMAP(TM) offering in the United States, called MolecularHealth(TM) RxAssistance. This new service is a value-added benefit for patients and their doctors, providing a level of reimbursement support not previously seen in the molecular diagnostic industry. Unlike reimbursement services offered by other companies that only assess insurance options for the molecular diagnostic test itself, RxAssistance evaluates insurance options for the therapies recommended by its tests. RxAssistance is designed to help streamline the reimbursement process and provide physicians and patients with support and education about payer reimbursement for treatment options. Each patient's TreatmentMAP results report and insurance information is reviewed by MolecularHealth's reimbursement specialist, a Certified Professional Coder(R), prior to results being sent to the physician. Off-label or investigational products recommended for treatment are flagged and information is gathered, including the likelihood a payer will reimburse for the suggested treatments and any additional information that will be needed to receive reimbursement, such as a letter of medical necessity. RxAssistance has been integrated into TreatmentMAP's end-to-end offering and is currently included as a value-added component of all orders. When a physician receives a patient's results report, they also receive an accompanying RxAssistance report, providing information on pre-authorization, patient responsibility for co-pays and deductibles, letters of medical necessity, and step therapy requirements and/or medical benefit formularies.
Molecularhealth Adds Fadi Braiteh to its Advisory Board
Aug 7 14
MolecularHealth announced the addition of Fadi Braiteh, M.D., to its advisory board. Dr. Braiteh is a practicing oncologist with the Comprehensive Cancer Centers of Nevada, and a leading specialist on gastro-intestinal, digestive system and breast cancer oncology. He joins a board comprised of numerous nationally and internationally-recognized oncology and pathology experts.
MolecularHealth Expands U.S. Sales Team with Three Strategic New Hires
Jul 29 14
MolecularHealth announced the hiring of three new members of its U.S. sales team, filling the roles of regional vice president and senior account directors. Since the company’s April launch of its cancer treatment decision support offering, TreatmentMAP™, MolecularHealth is seeing increased interest in and demand for its offering, which will be supported by its expanded sales team. The three new additions to the sales team all come with strong backgrounds in pharmaceutical and diagnostics sales, each a former employee of Life Technologies. Matt Brunner, who will report to Dye, boards as regional vice president for the Western region, bringing over 15 years of sales experience, dedicated primarily to oncology. He is joined by Bruce Mrachek and Lee Stuart, who will serve as senior account directors for the Southwest and Southeast regions, respectively.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|